Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. MicroRNA-based classifiers for diagnosis of oral cavity squamous cell carcinoma in tissue and plasma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A failure-type specific risk prediction tool for selection of head-and-neck cancer patients for experimental treatments

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Synchronous, bilateral tonsillar carcinomas: Patient characteristics and human papillomavirus genotypes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. On the relation between improved loco-regional control and disease-free survival in head-and-neck cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Very Early Response Evaluation by PET/MR in Patients with Lung Cancer-Timing and Feasibility

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Lymphoblastic Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group (ILROG)

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

OBJECTIVES: A previously published prognostic model in patients with head and neck squamous cell carcinoma (HNSCC) was validated in both a p16-negative and a p16-positive independent patient cohort and the performance was compared with the newly adopted 8th edition of the UICC staging system.

MATERIALS AND METHODS: Consecutive patients with HNSCC treated at a single institution from 2005 to 2012 were included. The cohort was divided in three. 1.) Training cohort, patients treated from 2005 to 2009 excluding patients with p16-positive oropharyngeal squamous cell carcinomas (OPSCC); 2.) A p16-negative validation cohort and 3.) A p16-positive validation cohort. A previously published prognostic model (clinical model) with the significant covariates (smoking status, FDG uptake, and tumor volume) was refitted in the training cohort and validated in the two validation cohorts. The clinical model was used to generate four risk groups based on the predicted risk of disease recurrence after 2 years and the performance was compared with UICC staging 8th edition using concordance index.

RESULTS: Overall 568 patients were included. Compared to UICC the clinical model had a significantly better concordance index in the p16-negative validation cohort (AUC = 0.63 for UICC and AUC = 0.73 for the clinical model; p = 0.003) and a borderline significantly better concordance index in the p16-positive cohort (AUC = 0.63 for UICC and 0.72 for the clinical model; p = 0.088).

CONCLUSION: The validated clinical model provided a better prognostication of risk of disease recurrence than UICC stage in the p16-negative validation cohort, and similar prognostication as the newly adopted 8th edition of the UICC staging in the p16-positive patient cohort.

OriginalsprogEngelsk
TidsskriftOral Oncology
Vol/bind81
Sider (fra-til)52-60
Antal sider9
ISSN1368-8375
DOI
StatusUdgivet - jun. 2018

ID: 54657259